Using value of information analysis to inform publicly funded research priorities

IntroductionThe purpose of this article is to demonstrate the application and feasibility of using value of information analysis to help set priorities for research as part of the UK National Health Service (NHS) Health Technology Assessment Programme. Probabilistic decision analysis and value of information methods were applied to a research topic under consideration by the National Coordinating Centre for Health Technology Assessment (NCCHTA), in the UK. The case study presented considers whether long-term, low-dose antibacterial treatment of recurrent urinary tract infections (UTIs) in children is effective and cost effective compared with short-term antibacterial therapy.MethodsA probabilistic decision-analytic model was developed, within which evidence from published sources was synthesised. Eight subgroups were considered and defined in terms of sex and presence of vesico-ureteral reflux (VUR). Costs were assessed from an NHS perspective, and benefits were expressed as quality-adjusted life-years (QALYs). Simulation methods were used to determine the probability that alternative therapies would be cost effective at a range of threshold values that the NHS may attach to an additional QALY. Value of information analysis was used to quantify the cost of uncertainty associated with the decision about which therapy to adopt, which indicates the maximum value of future research. The feasibility and practicality of using value of information methods to help inform research prioritisation was evaluated.ResultsAt a threshold value for an additional QALY of £30 000, long-term antibacterial treatment may be regarded as cost effective for all eight patient groups. There was, however, substantial uncertainty surrounding the choice of antibacterial.Discussion/conclusionThe use of value of information methods was feasible and could inform research prioritisation for the NHS. In the context of this specific decision faced by the NHS, the results show that long-term low-dose antibacterials for preventing recurrent UTIs may be cost effective, based on current evidence. However, the analysis suggests that further primary research with longer follow-up may be worthwhile, particularly for girls with no VUR.

[1]  C. Murray,et al.  Burden of disease--implications for future research. , 2001, JAMA.

[2]  B. Arant.  Vesicoureteric reflux and renal injury. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  Kimberly M. Thompson,et al.  The Value of Improved National Exposure Information for Perchloroethylene (Perc): A Case Study for Dry Cleaners , 1997 .

[4]  Stephen D. Roberts,et al.  Examining alternative End-Stage Renal Disease (ESRD) therapies through simulation , 1979, SIML.

[5]  O. Salvatierra,et al.  The 1989 report of the North American Pediatric Renal Transplant Cooperative Study , 1990, Pediatric Nephrology.

[6]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[7]  O. Nielsen,et al.  Nitrofurantoin versus Trimethoprim Prophylaxis in Recurrent Urinary Tract Infection in Children , 1990, Acta paediatrica Scandinavica.

[8]  S. Stearns,et al.  Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. , 2003, Health technology assessment.

[9]  D. Williams.  Vesico-Ureteric Reflux , 1962, Postgraduate medical journal.

[10]  N. Powe,et al.  The relation between funding by the National Institutes of Health and the burden of disease. , 1999, The New England journal of medicine.

[11]  M H Ebell,et al.  Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. , 1998, The Journal of family practice.

[12]  A E Ades,et al.  Markov Chain Monte Carlo Estimation of a Multiparameter Decision Model: Consistency of Evidence and the Accurate Assessment of Uncertainty , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  M. Drummond,et al.  PRIORITIZING INVESTMENTS IN HEALTH TECHNOLOGY ASSESSMENT , 2000, International Journal of Technology Assessment in Health Care.

[14]  F. Kronenberg,et al.  Impact of apolipoprotein(a) phenotypes on long-term renal transplant survival. , 2001, Journal of the American Society of Nephrology : JASN.

[15]  S. Hansson,et al.  Vesico‐ureteric reflux: occurrence and long‐term risks , 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[16]  S. Parente,et al.  Priority Setting in Medical Technology and Medical Practice Assessment , 1990, Medical care.

[17]  J. Smedley.  National Institute of Health and Clinical Excellence www.nice.org.uk , 2006 .

[18]  Robert Schlaifer,et al.  Probability And Statistics For Business Decisions , 1960 .

[19]  G. Howie,et al.  CONTROLLED TRIAL OF THERAPY IN COVERT BACTERIURIA OF CHILDHOOD , 1975, The Lancet.

[20]  M. Drummond,et al.  The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment , 1997, Journal of health services research & policy.

[21]  G. Torrance,et al.  Measurement of quality of life in end-stage renal disease: the time trade-off approach. , 1987, Clinical and investigative medicine. Medecine clinique et experimentale.

[22]  E. Stokland,et al.  The natural history of bacteriuria in childhood. , 1997, Infectious disease clinics of North America.

[23]  J. Stansfeld.  Duration of treatment for urinary tract infections in children. , 1975, British medical journal.

[24]  S. Downs.  Technical Report: Urinary Tract Infections in Febrile Infants and Young Children , 1999, Pediatrics.

[25]  R. Grüneberg,et al.  CONTROLLED TRIAL OF PROPHYLACTIC TREATMENT IN CHILDHOOD URINARY-TRACT INFECTION , 1978, The Lancet.

[26]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.

[27]  J. Winberg,et al.  Morbidity, age and sex distribution, recurrences and renal scarring in symptomatic urinary tract infection in childhood. , 1975, Kidney international. Supplement.

[28]  M. Drummond,et al.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.

[29]  A E Ades,et al.  Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.